제이투케이바이오
Financials
Valuation Metrics
제이투케이바이오's Market Cap is ₩567B. At end of 2025 it was ₩503B. Ranked #1693 of 2,421 in KR market (top 70%), #1021 of 1,640 on KOSDAQ (top 62%), #181 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 56.66B KRW | KR#1,693/2,421 Sec#181/231 |
| Revenue | 43.90B KRW | KR#1,865/2,421 Sec#132/231 |
| Net Income | 5.81B KRW | KR#1,149/2,421 Sec#74/231 |
| Total Assets | 43.42B KRW | KR#2,260/2,421 Sec#206/231 |
| Net Assets | 36.57B KRW | KR#2,105/2,421 Sec#184/231 |
| Employees | 56 | KR#2,005/2,421 Sec#180/231 |
| Value | ||
| P/E | 9.75x | KR#785/2,421 Sec#40/231 |
| P/B | 1.55x | KR#1,789/2,421 Sec#127/231 |
| PEG | 0.11x | KR#435/2,421 Sec#20/231 |
| P/S | 1.29x | KR#1,552/2,421 Sec#90/231 |
| EV/EBITDA | 7.36x | KR#411/2,421 Sec#16/231 |
| FCF Yield | 3.57% | KR#946/2,421 Sec#58/231 |
| Profitability | ||
| ROE | 15.89% | KR#282/2,421 Sec#18/231 |
| ROA | 13.39% | KR#154/2,421 Sec#12/231 |
| Op. Margin | 14.80% | KR#310/2,421 Sec#29/231 |
| Revenue Growth | 50.99% | KR#203/2,421 Sec#28/231 |
| Earnings Growth | 85.09% | KR#431/2,421 Sec#30/231 |
| Financial Health | ||
| Debt Ratio | 18.72% | KR#335/2,421 Sec#45/231 |
| Total Debt | 400.0M KRW | KR#2,003/2,421 Sec#187/231 |
| FCF | 2.03B KRW | KR#1,084/2,421 Sec#77/231 |
| Cash | 9.21B KRW | KR#1,743/2,421 Sec#152/231 |
| Current Ratio | 4.11x | KR#368/2,421 Sec#57/231 |
| Net Debt/EBITDA | -1.36x | KR#314/2,421 Sec#15/231 |
| Dividend | ||
| Div. Yield | 2.56% | KR#736/2,421 Sec#36/231 |
| Div. Growth | 25.00% | KR#391/2,421 Sec#20/231 |
| Performance | ||
| 1Y Return | 0.83% | KR#717/2,421 Sec#47/231 |
| 1M Return | 12.02% | KR#408/2,421 Sec#28/231 |
| From 52W High | -24.65% | KR#376/2,421 Sec#20/231 |
| 1Y MDD | -35.35% | KR#422/2,421 Sec#32/231 |
| Trading | ||
| Volume | 87,302 shares | KR#844/2,421 Sec#78/231 |
| Trading Value | 845.9M KRW | KR#768/2,421 Sec#77/231 |
| Foreign Own. | 1.72% | KR#1,741/2,421 Sec#166/231 |
| Per Share | ||
| EPS | 994 KRW | KR#723/2,421 Sec#48/231 |
| BPS | 6,254 KRW | KR#1,331/2,421 Sec#91/231 |
Company Info
J2K Bio, established in 2016 and listed on KOSDAQ in March 2024, produces and sells cosmetic raw materials. The company is a cosmetic new material developer that swiftly meets client demands through innovative natural product methods and new material development using fermented microorganisms, offering a competitive edge. It focuses on developing new active ingredients derived from natural, organic, and biomaterials, providing safer alternatives to synthetic compounds. J2K Bio is headquartered in Cheongju-si, Chungcheongbuk-do.